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Abstract
Background: Limited information is available on the relationship between nevirapine plasma concentrations and virologic
response or liver toxicity in Chinese patients with HIV infection. The objective of this prospective study was to test this
relationship and to determine the minimal therapeutic trough concentration of nevirapine for Chinese patients.
Methods: A total of 227 HIV-infected, treatment naı ¨ve patients were enrolled into this study. Blood samples were taken at
Ctrough (12 hr postdose) and C2 (2 hr postdose) for measurement of nevirapine concentrations 6 months after treatment
initiation. Therapeutic outcomes, viral load and CD4 cell count, were assessed at 3 and 6 months after starting therapy,
while the evaluation of hepatotoxicity was undertaken 12 months after nevirapine treatment.
Results: A significant correlation between nevirapine trough concentrations and viral load was noticed after 6 months of
treatment, particularly in patients with partial response and viral failure (p,0.01). The therapeutic Ctrough of nevirapine
for Chinese patients was determined to be 3.9 mg/ml using the receiver operating characteristic curve. Virologic failure
was observed in 21% (6/29) of patients with low nevirapine concentrations (,3.9 mg/ml) versus 5% (4/87) in patients
with concentrations higher than 3.9 mg/ml (p=0.015). Hepatotoxicity was significantly associated with the median
nevirapine trough concentrations among male patients (8.20 vs. 5.48 mg/ml, p=0.015) and hepatitis C virus co-infection
(p=0.039).
Conclusions: Among Chinese patients with HIV infection, the therapeutic Ctrough of nevirapine was 3.9 mg/ml, higher than
the recommended 3.0 mg/ml. The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the
benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize
nevirapine containing antiretroviral therapy.
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Introduction
Highly active antiretroviral therapy is considered an effective
approach for the management of HIV/AIDS. Due to its low cost
and high efficacy, nevirapine -containing regimens are often
preferable to others in resource-limited countries [1]. Approxi-
mately 80% Chinese patients receiving antiretroviral therapy are
currently on nevirapine-containing regimens. The pharmacolog-
ical characteristics of nevirapine make it an attractive candidate
for therapeutic drug monitoring, as previous studies have indicated
a significant relationship between nevirapine trough concentra-
tions and virologic response [2,3,4]. Also, high concentrations are
linked to an increased risk of liver toxicity and hepatic injury in
patients with chronic hepatitis C [5,6,7,8]. Inter-individual
variability of nevirapine plasma concentrations among HIV-
infected adults was common in routine clinical practice (,50%)
[9]. The variability could be partially explained by the differences
in ethnicity, gender, polymorphisms in enzyme and transporter
genes, hepatitis virus co-infection, and concomitant medications
[10,11,12,13].
As the majority of the previous studies were performed among
Caucasian subjects, there is generally a lack of information
regarding the efficacy and safety of nevirapine in Chinese HIV-
infected patients. A number of studies exploring the association of
exposure to nevirapine with virologic response yielded a target
trough concentration of ,3.0 mg/l [2,4]; however, this value has
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26739not been confirmed among Chinese patients. In addition, the
relationship between liver toxicity and nevirapine concentrations
has not been established conclusively, though several studies
indicate transaminase elevations are related to nevirapine
exposure [6,8]. Therefore, the overall objective of the present
study was to investigate the relationship between nevirapine
concentrations, virologic response and liver toxicity in Chinese
HIV-infected patients.
Results
A. Virologic Response
Of 227 HIV-positive antiretroviral-naive patients screened, 173
were treated by a fixed combination antiretroviral therapy
containing nevirapine for at least 24 weeks and included in the
virologic response analysis (Figure 1). Demographic characteristics
of these patients are summarized in Table 1. There were no
Figure 1. Flow of patient participation through the clinical trial. ART: antiretroviral therapy; VL: viral load; AZT: zidovudine; DDI: didanosine;
NVP: nevirapine; 3TC: lamivudine; D4T: stavudine; Ctrough: trough concentrations of nevirapine; C2: nevirapine concentrations 2-h post-dose.
doi:10.1371/journal.pone.0026739.g001
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(complete response, partial response and viral failure) at baseline.
Plasma nevirapine concentrations were measured 24 weeks after
treatment initiation, including Ctrough (n=116) and C2 (n=49).
The overall incidence of virologic failure was 10% (18/173).
Nevirapine Ctrough and C2 in the three groups are summarized in
Table 2. The median Ctrough in patients with virologic failure was
significantly lower than that in partial response and complete
response groups (3.81 vs. 5.65 and 5.18 mg/ml, respectively,
p=0.018), whereas no significant differences were noted between
partial and complete response groups. In contrast, no significant
difference in median C2 was noted among these groups (p=0.608).
A relatively large inter-patient variability in nevirapine Ctrough was
noted (Figure 2, Table 2). Linear regression analysis indicated a
significant linear relationship between viral load and Ctrough
(r=0.327, p,0.05) for all patients, particularly when limited to
patients with a partial response or viral failure (r=0.619, P,0.01).
In order to determine the nevirapine Ctrough threshold for
therapeutic drug monitoring in Chinese HIV-infected patients, the
receiver operating characteristic curve (ROC curve, Figure 3) was
used to evaluate the sensitivities and specificities of different cut-off
values as shown in Table 3. While the recommended threshold of
3.0 mg/ml corresponded to a low sensitivity of 40% and a high
specificity of 88% for viral failure, a new threshold value of
3.9 mg/ml would have a significantly increased sensitivity of 60%
(p=0.005) and an acceptable specificity of 78% (p=0.06).
Virologic failure was observed in 21% of patients with concen-
trations ,3.9 mg/ml versus 5% with concentrations higher than
3.9 mg/ml (p=0.015) (Table 4).
B. Nevirapine Related Liver Toxicity
Of the 227 patients screened, 191 patients were qualified for the
liver toxicity analysis (Figure 1). The incidence of liver toxicity was
71% (136/191), including 43 patients (23%) with severe liver
toxicity within 12 weeks of starting therapy. Demographic
characteristics of those with and without severe liver toxicity are
summarized in Table 5. There were no statistically significant
differences between these groups at baseline, except for the body
weight.
Nevirapine Ctrough and C2 in different groups are summarized
in Table 6. There was no significant difference of Ctrough between
these groups (median 5.91 vs. 5.54 mg/ml, p=0.290). Previous
Table 1. Baseline Characteristics of Patients Included in Virologic Response Analysis.
Total
n=173
Complete Response
(,50 copies/ml)
n=126
Partial Response
(50–400 copies/ml)
n=32
Virologic Failure
(.400 copies/ml)
n=15 p
Male -n (%) 90 (52) 64 (51) 18 (56) 8 (53) 0.854
Transmission route -n (%) 0.674
Blood transfusion 50 (29) 37 (29) 9 (28) 4 (27)
Sexual 82 (47) 56 (44) 17 (53) 9 (60)
Others 41 (24) 33 (26) 6 (19) 2 (13)
Co-infection -n (%)
Hepatitis B virus 12 (7) 7 (6) 3 (9) 2 (13) 0.445
Hepatitis C virus 44 (25) 34 (27) 6 (19) 4 (27) 0.630
Age (yrs) -median (IQR) 37 (30, 45) 37 (29, 43) 37 (32, 50) 35 (27, 46) 0.343
Weight (kg) -median (IQR) 56 (50, 65) 56 (50, 67) 55 (49, 60) 60 (53, 70) 0.152
CD4 cell count (cells/L) - mean 6 SD 203691 204686 1976108 207698 0.930
HIV-1 RNA (log10 copies) - mean 6 SD 4.5360.70 4.4660.67 4.6260.77 4.8960.69 0.071
Three patient groups, complete response with viral load ,50 copies/ml, partial response with viral load 50–400 copies/ml and virologic failure with viral load greater
than 400 copies/ml, were included for analysis.
doi:10.1371/journal.pone.0026739.t001
Figure 2. Linear regression analysis of decrease in viral load
(VL) and trough concentrations of nevirapine (NVP Ctrough). The
log transformation of decrease in viral load (dlogVL) was significantly
correlated with trough nevirapine concentrations (NVP Ctrough, mg/ml)
among (A) all patients (r=0.327, p,0.05); and (B) patients with partial
response (VL 50–400 copies/ml) and virologic failure (VL.400 copies/
ml) (r=0.619, p,0.01).
doi:10.1371/journal.pone.0026739.g002
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baseline liver function are independent risk factors for nevirapine
related liver toxicity. Thus, the impact of gender, baseline liver
function and presence of hepatitis C virus antibody on Ctrough
were evaluated. A similar analysis for C2 was not possible due to
the small number of C2 samples. A significantly higher median
Ctrough was noted in males with severe liver toxicity in comparison
to those without severe toxicity (8.20 vs. 5.48 mg/ml, p=0.015).
No significant differences were observed in Ctrough medians in
other subgroups with and without severe hepatotoxicity (Table 6).
Baseline CD4+ T cell count was not statistically associated with
the incidence of severe liver toxicity among female Chinese
patients, 29% (9/31) and 16% (10/63) in the patients with the
baseline CD4+ T count .250/mm
3, and #250/mm
3, respec-
tively (p=0.184). The hepatitis C virus co-infection rate was 29%
(56/191) in our study population. Active HCV co-infection,
defined as HCV RNA .10
3copies/ml, led to a significantly higher
incidence of liver toxicity, 44% (10/23) compared to 18% (6/33)
among patients without active HCV co-infection (p=0.039,
Table 7).
Discussion
This study found a significant correlation between nevirapine
trough concentrations, virologic response and liver toxicity among
Chinese HIV-infected patients. While patients with low nevirapine
Ctrough have a significantly higher risk of virologic failure, those
with a high Ctrough are at greater risk of severe liver toxicity,
especially male patients. Our data suggest that for the optimal
virologic outcomes, a trough nevirapine concentration of
$3.9 mg/ml should be sustained throughout the treatment course
for Chinese patients with HIV infection. To our knowledge, this is
the first report of an association between nevirapine concentration
and clinical outcomes in Chinese patient population. This adds to
the evidence supporting the usefulness of therapeutic drug
monitoring in optimizing treatment of this population.
The relationship between nevirapine concentrations and
virologic response has been explored in previous studies, primarily
including Caucasians and African Americans. The INCAS trial
suggested that a nevirapine plasma concentration range of 3.45–
3.88 mg/ml at week 12 was predictive of virologic success after 52
weeks of therapy [4]. A more recent clinical trial of 74 patients
confirmed that patients with virologic success had higher
concentrations than those with virologic failure (mean 6 SD,
4.5562.08 vs. 2.5761.64 mg/ml, p=0.003) [3]. Our results in
Chinese patients with HIV infection are consistent with the
previous results obtained from clinical trials on Caucasians and
Africans, higher nevirapine trough concentrations were associated
with a lower rate of virologic failure. The median levels of Ctrough
among Chinese patients with partial and complete response after a
Table 2. Relationship between Plasma Nevirapine Concentrations [Median (IQR), mg/ml] and Virologic Responses.
Complete Response
(,50 copies/ml)
Partial Response
(50–400 copies/ml)
Virologic Failure
(.400 copies/ml) p
Ctrough 5.18 (3.97, 7.16) (n=87) 5.65 (4.69, 7.78) (n=19) 3.81 (2.14, 5.36) (n=10) 0.018
C2 6.85 (5.47, 9.16) (n=34) 6.91 (3.93, 8.21) (n=11) 6.49 (4.82, 8.19) (n=4) 0.608
Ctrough: trough concentrations; C2: concentrations at 2-h post-dose. Three patient groups, complete response with viral load ,50 copies/ml, partial response with viral
load 50–400 copies/ml and virologic failure with viral load greater than 400 copies/ml, were included for analysis.
doi:10.1371/journal.pone.0026739.t002
Figure 3. Evaluation of nevirapine trough concentrations as a
prognostic factor for virologic failure using ROC curve. The
receiver operating characteristic (ROC) curve was utilized to evaluate
nevirapine trough concentrations as a prognostic factor for virologic
failure accommodating both sensitivity and specificity. A cut-off value
of 3.9 mg/ml was determined for Chinese HIV+ patients with a
significantly improved sensitivity of 60% in comparison to the original
cut-off of 3.0 mg/ml (p,0.05, Table 3).
doi:10.1371/journal.pone.0026739.g003
Table 3. Sensitivity and Specificity of Cut-Off Values of
Nevirapine Trough Concentrations Based on Receiver
Operating Characteristic (ROC) Curve Analysis.
Ctrough (mg/ml) Sensitivity (%) Specificity (%)
2.4 40 95
3.0* 40 88
3.4 40 83
3.8 50 78
3.9** 60 78
4.0 60 76
5.2 70 54
5.4 80 52
5.6 90 50
6.2 100 37
*Currently used in clinical practice for Chinese HIV+ patients,
**New therapeutic nevirapine Ctrough based on the data from this study.
doi:10.1371/journal.pone.0026739.t003
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patients with viral failure (Table 2). The regression analysis
revealed a significant linear relationship between Ctrough and viral
load (Figure 2). However, no relationship between C2 and
treatment outcomes was detected in our study population.
No target trough concentration of nevirapine has been
established for treatment success in Chinese patients. Although
treatment guidelines recommend various target thresholds for
nevirapine trough concentrations, these data are predominately
from studies in Caucasian and African American patients, which
may not be applicable to patients of Asian descent. Additionally,
the current recommendations for nevirapine Ctrough thresholds are
not completely in agreement. For instance, an observational
cohort analysis [2] suggested 3.0 mg/ml as the minimal Ctrough
because risk of virologic failure in patients with nevirapine
concentrations #3 mg/ml was significantly increased (relative risk
5.0, 95% CI 1.8–13.7). Another study of 178 patients identified a
mean plasma concentration of 4.3 mg/ml to be an independent
factor for virologic failure [14]. Although the cut-off of 3.0 mg/ml
was tentatively adapted to clinical practice in China according to
the 2006 Chinese HIV Treatment Guidelines, this level does
ensure treatment success as virologic failures often occur among
patients with concentrations .3.0 mg/ml. This phenomenon is
possibly explained by racial or ethnicity variability in the effective
concentration needed to ensure therapeutic success and an
underrepresentation of Chinese patients in previous studies.
According to our data, the currently accepted threshold for
nevirapine Ctrough (3 mg/ml) had an unfavorable sensitivity (40%)
and may lead to a high incidence of virologic failure. The
sensitivity would be improved to 60% without a marked decrease
of specificity using 3.9 mg/ml. Therefore, to minimize the risk of
virologic failure, we believe a more suitable nevirapine Ctrough
threshold is 3.9 mg/ml in Chinese patients, a 30% increase from
the current nevirapine Ctrough recommendation (3 mg/ml).
Liver toxicity is the most common adverse effect associated with
nevirapine treatment while results from previous studies on the
relationship of nevirapine Ctrough and liver toxicity are not in
agreement. Gonza ´lez de Requena et al [6] investigated the effect of
nevirapine plasma exposure on liver enzyme elevations and
observed that among patients with chronic hepatitis C co-
infection, nevirapine concentrations .6 mg/ml were associated
with a 92% risk of liver toxicity. Therefore, monitoring nevirapine
levels, especially in individuals with chronic hepatitis C co-
infection, might be warranted. A multivariate linear regression
analysis [15] also revealed that high Ctrough at week 24 was an
independent predictor for liver enzyme elevations. However, a
prospective population pharmacokinetic study [5] and the 2NN
study [11] suggested no correlation between nevirapine trough
concentrations and liver enzyme levels, after corrected for known
covariates such as gender, CD4 cell count at baseline, and
hepatitis C coinfection.
Our data confirmed no significant differences in nevirapine
Ctrough or C2 between patients with and without severe liver
toxicity. Several confounding factors such as gender, HCV co-
infection and baseline liver function have been suggested for
nevirapine exposure and liver toxicity [16,17], although no
association between those factors and the occurrence of severe
liver toxicity were detected in our patients. The nevirapine Ctrough
Table 4. Risk of Viral Failure in Chinese HIV+ Patients Based
on Nevirapine Trough Concentration of 3.9 mg/ml.
Virologic Response - n (%) p
Complete and partial response Virologic Failure
,3.9 23 (79) 6 (21)
$3.9 83 (95) 4 (5) 0.015
Two patient groups, complete and partial response with viral load ,50 copies/
ml and 50–400 copies/ml, respectively and virologic failure with viral load
greater than 400 copies/ml, were included for analysis.
doi:10.1371/journal.pone.0026739.t004
Table 5. Baseline Characteristics of Patients Included in the Liver Toxicity Analysis.
Total n=191
Severe
Hepatotoxicity n=42
Without Severe
Hepatotoxicity n=149 p
Male -n (%) 94 (49) 19 (45) 75 (50) 0.342
Transmission route -n (%) 0.224
Blood transfusion 57(30) 12(29) 46(31)
Sexual 95(50) 25(58) 70(47)
Others 38(20) 5(12) 33(22)
Co-infection -n (%)
Hepatitis C virus 56(29) 16(38) 40(27) 0.112
Hepatitis B virus 11(6) 0(0) 11(7) 0.060
Age (yrs) -median (IQR) 37(29, 43) 35(29, 43) 37(29, 43) 0.683
Weight (kg) -median (IQR) 56(50, 64) 55(50, 61) 56(52, 65) 0.020
ALT (U/L) -median (IQR) 27(16, 48) 29(18, 48) 29(17, 49) 0.207
AST (U/L) -median (IQR) 29(22, 43) 29(22, 48) 31(22, 43) 0.578
Tbil (mmol/L) -median (IQR) 11(8, 15) 12(8, 16) 11(8, 15) 0.764
CD4 cell count (cells/L) - mean6SD 210690 209698 211688 0.668
HIV-1 RNA (log10 copies) - mean6SD 4.4960.69 4.3960.74 4.5160.67 0.523
ALT: alanine aminotransferase; AST: aspartate aminotransferase; Tbil: total bilirubin. Two patient groups, with and without severe hepatotoxicity, were included for
analysis.
doi:10.1371/journal.pone.0026739.t005
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toxicity. However, such relationship was not observed in females
and other subgroups, suggesting the nevirapine-related liver
toxicity might be gender dependent. While previous studies
[17,18] have demonstrated that female gender combined with
high CD4+ T cell count significantly increased the incidence of
nevirapine-induced liver toxicity, our data found a non-significant,
modest increase of liver toxicity in female patients with high
baseline CD4+ count (.250/mm
3) (29% vs. 16%, p=0.184). This
may be due to the relatively small sample size, along with racial
and ethnic factors.
Our data confirmed that hepatitis C virus co-infection was
significantly associated with an increased risk of severe liver
toxicity in Chinese HIV+ patients [19]. A prospective study [16] of
568 patients, primarily Caucasians and African Americans, also
demonstrated a higher risk of severe hepatotoxicity among patients
with chronic viral hepatitis C and B infections. However, such risk
was remarkably reduced by concurrent interferon-based therapy
with sustained HCV clearance in patients with HIV/HCV
coinfection [20]. In the present study, Chinese HIV+ patients
with high HCV RNA levels had a significantly greater risk of
severe liver toxicity than those patients with low HCV RNA levels.
This suggests that active HCV coinfection, correlated with HCV
RNA levels, might be a more accurate predictor of nevirapine
related liver toxicity than positive HCV antibody alone. Although
the underlying mechanisms of this hepatotoxicity are not fully
understood, an association between increased HCV-specific
immune response and T cell activation have been suggested in
previous studies [21]. Therefore, based on our results, nevirapine
containing regimens should be avoided in Chinese patients with
active HCV coinfection until sustained control of HCV is
achieved.
The use of nevirapine peak concentration as a monitoring
parameter was explored in this study, as limited information is
available on this topic to date. Nevirapine C2 was chosen to
represent nevirapine peak concentration, based on previous
pharmacokinetic results that indicate the mean time to reach
nevirapine peak concentration was 2.01 hours [22]. Unfortunate-
ly, nevirapine C2 had no correlation with any clinical outcomes
evaluated in this study. This may be due to inter-patient
variability, i.e. the exact peak time for nevirapine is different from
patient to patient. Thus, it is difficult to collect samples that truly
represent peak concentrations. Our data suggest that the clinical
use of nevirapine peak concentrations may not be practical. Future
studies using other metrics, such as area under the time-
concentration curve derived from population analysis, are
warranted to explore the relationship between pharmacokinetics
of nevirapine and clinical outcomes in Chinese HIV+ patients.
There were several limitations to this multi-centre prospective
study in patients receiving nevirapine-containing therapy. The
cohort was relatively small and heterogeneous, including patients
with various underlying medical conditions. However, our patients
reflected a typical Chinese HIV+ clinical cohort [1], making the
results applicable to the study population. Selection bias was
prevented by patient randomization. Because only trough and 2-
hour post dose concentrations were included in our study, other
untested pharmacokinetic metrics including exposure and clear-
ance may be of more clinical relevance. The strength of some of
Table 6. Impact of Gender and Hepatitis C Virus Co-Infection on Nevirapine Concentrations (mg/ml) in Patients Experiencing
Severe Hepatotoxicity.
Severe Hepatotoxicity Without Severe Hepatotoxicity p
Ctrough -median (IQR) 5.91 (4.45, 7.60), n=32 5.54 (4.33, 740), n=120 0.290
Gender
Male 8.20 (5.07, 11.20), n=13 5.48 (4.31, 7.21), n=62 0.015
Female 5.43 (4.00, 6.90), n=19 5.56 (4.41, 7.53), n=58 0.543
HCV Antibody
Positive 7.80(4.50, 10.22), n=13 6.13(4.16, 7.93), n=37 0.157
Negative 5.48(4.00, 6.90), n=19 5.21(6.39, 7.00), n=83 0.884
C2 -median (IQR) 6.06(4.63, 7.48), n=5 6.29(5.20, 7.77), n=29 0.715
Ctrough: trough concentrations; C2: concentrations at 2 h post-dose; HCV: hepatitis C virus; ALT: alanine aminotransferase. Two patient groups, with and without severe
hepatotoxicity, were included for analysis.
doi:10.1371/journal.pone.0026739.t006
Table 7. Risk of Severe Hepatotoxicity in Patients with Different Baseline CD4 Count and Hepatitis C Virus RNA Level.
Group – n (%) p
Severe hepatotoxicity Without Severe Hepatotoxicity
Baseline CD4 count (females)
.250/mm3 9 (29) 22 (71) 0.184
#250/mm3 10 (16) 53 (84)
HCV RNA level
.10
3copies/ul 10 (43) 13 (57) 0.039
#10
3copies/ul 6 (18) 27 (82)
doi:10.1371/journal.pone.0026739.t007
Responses to Nevirapine in Chinese HIV+ Patients
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26739the associations presented in this study should be interpreted with
caution, owing to the relatively small sample size. Finally,
unrecognized confounders may have influenced nevirapine
concentrations, e.g. dosing in relation to food, concurrent
medications, or genetic polymorphisms of CYP2B6, which
significantly influenced nevirapine metabolism in HIV-infected
patients in Uganda [19]. However, genotyping was not routinely
available, and dose adjustments based on results of genotypic tests
have not been proposed as yet for nevirapine.
In conclusion, this study supports the association between
nevirapine concentrations and treatment outcomes in Chinese
HIV+ patients. For patients with low trough concentrations, dose
adjustments should be considered to achieve and sustain a median
nevirapine trough concentration greater than 3.9 mg/ml. Given
the inter-patient variability and the lack of an upper pharmaco-
kinetic threshold for nevirapine associated hepatotoxicity, dose
modification should be considered only in symptomatic patients.
Finally, further studies are warranted, as a therapeutic range for
nevirapine in Chinese HIV+ patients remains elusive.
Methods
Study subjects
A prospective, randomized study was conducted among
antiretroviral-naı ¨ve HIV-infected patients of the Han nationality
in China. The study protocol was in accordance with the
Declaration of Helsinki and approved by the Ethics Committee
of participating hospitals including Peking Union Medical College
Hospital, Beijing Youan Hospital, Beijing Ditan Hospital, The
First Affiliated Hospital, Henan Medical University, Xian Tangdu
Hospital, The Second Affiliated Hospital, Xiangya Medical
University, Shanghai Public Health Center, Shenzhen CDC,
The 8
th Hospital of Guangzhou, HIV/AIDS Care Center of
Yunnan, and Zhejiang Medical University. Written consent was
obtained from each patient. Eligible patients were aged from18 to
65 years, and received a standard regimen that included
nevirapine and two nucleoside reverse transcriptase inhibitors
between January 2002 and November 2008 from thirteen HIV/
AIDS Clinical Centers in China. A total of 227 patients were
enrolled in this study (Figure 1). The original study design was
published previously [1].
Nevirapine (Desano Pharma, Shanghai, China) was admin-
istered at 200 mg once daily for 2 weeks and 200 mg twice
daily thereafter. The bioequivalence of nevirapine in reference
to ViramuneH from Boehringer Ingelheim was demonstrated in
the previous studies [23]. Medication adherence was monitored
by self-report using validated surveys and directly observed
therapy (DOT). Main exclusion criteria were acute HIV
infection, AIDS-defining illness within 2 weeks of entry, white
blood cell count ,2.0610
9/L, absolute neutrophil count
,1.0610
9/L, hemoglobin level ,90 g/l, platelet count
,0.75610
12/L, transaminase and alkaline phosphatase level
.3 times the upper limit of the normal range, bilirubin level
.2.5 times the upper limit of the normal range, and serum
creatinine level .1.5 times the upper limit of the normal range.
Patients were followed up prior to starting therapy, then 1, 2, 3,
6, 9 and 12 months after the initiation of treatment. During all
of the visits, the clinical assessment was performed and blood
samples were taken for liver function and plasma viral load
analyses.
Outcome measures
The primary efficacy outcome was virologic failure, defined as a
single plasma HIV-1 RNA concentration (viral load) .400
copies/ml at week 24. Complete virologic response was defined
as a viral load ,50 copies/ml at week 24, whereas partial virologic
response was defined as a viral load between 50 and 400 copies/ml
at week 24. The QUANTIPLEX HIV-1 RNA assay was used to
measure the plasma HIV-1 RNA concentrations. The limits of
detection of the assay, as indicated by the manufacturer, was
50,500,000 copies/ml.
All clinical adverse events and laboratory abnormal results were
documented. Severe liver toxicity was defined as laboratory
abnormalities greater than grade 3 (WHO, 1979), including a
significant increase (.5 times of normal upper limit) of aspartate
aminotransferase (AST), alanine aminotransferase (ALT) or total
bilirubin, severe clinical symptoms consistent with liver toxicity, or
a therapy change caused by liver toxicity during the first 12
months of treatment.
Plasma nevirapine concentration analyses
A plasma sample was collected at 2 h after oral administration
of nevirapine (C2) during DOT or prior to the morning dose for
the detection of trough concentration (Ctrough, at least 12-h
postdose). The nevirapine concentration in plasma was deter-
mined by a validated HPLC assay modified from a previous study
[24]. The nevirapine concentration were analyzed on a Shim-pack
CLC-ODS column (6 mmID615 cm, 5 mm) with a mobile phase
consisting of water-acetonitrile (23:77) at a flow rate of 1 ml/min,
and the wavelength for detection was 260 nm. Tegafur was used
as an internal standard. The calibration curve of nevirapine was
linear in the range of 0.05–10 mg/ml (r=0.9999), and the limit of
detection was 0.05 mg/ml. The RSDs of intra- and inter- run
validations were less than 7%. The mean recoveries fell in the
range of 90–110% for the high, middle and low concentrations.
All plasma samples collected at the 6
th month of nevirapine
treatment were assayed for concentrations. Additional plasma
samples were collected for concentration assessment if severe liver
toxicity presented. For patients without severe liver toxicity, the
nevirapine plasma concentrations were determined during the 12-
month follow-up visit.
Statistical analyses
All statistical analyses were performed using the SPSS 11.5
statistical package. Categorical variables were tested with Chi-
Square or Fisher’s exact test, and continuous variables were tested
with Kruskal-Wallis or student t-test. The cut-off value for the
effective range of plasma drug concentration was determined by
the receiver operating characteristic curve (ROC curve). For all
tests, p,0.05 was considered to be statistically significant.
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